Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07845552

PHASE4

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn how quickly omalizumab begins to work in people with food allergy. The main question it aims to answer is: * Does omalizumab begin to work as early as 2 to 4 weeks after after starting treatment in people with food allergy? Researchers will compare each participant's food challenge results at baseline before starting omalizumab, 2 to 4 weeks after starting omalizumab, and 4 to 6 months after starting omalizumab treatment. Participants will: * Have a baseline food challenge before starting omalizumab. * Start omalizumab treatment as prescribed by the participant's doctor as part of regular clinical care. * Have food challenges 2 to 4 weeks after starting omalizumab and again 4 to 6 months after starting omalizumab. * Have skin prick testing and blood tests at study visits.

Key Details

Gender

All

Age Range

1 Year - 30 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-10

Completion Date

2028-10

Last Updated

2026-10-14

Healthy Volunteers

Conditions

Food Allergy

Interventions

DRUG

Omalizumab

Prior to starting omalizumab, participants will undergo a baseline oral food challenge. Participants will then initiate omalizumab treatment as prescribed by their doctor as part of routine clinical care. After 2 to 4 weeks of treatment (following one to two doses of omalizumab), participants will undergo a first post-treatment oral food challenge to assess treatment response. After 4 to 6 months of omalizumab treatment, participants will undergo a second post-treatment oral food challenge. The study will conclude following the second post-treatment oral food challenge.

Inclusion Criteria: * Age 1 to 30 years. * Patients with diagnosed food allergy to at least one of the following foods (milk, egg, wheat, peanut, cashew, or walnut) who were prescribed omalizumab for food allergy in the clinical setting at the Johns Hopkins pediatric or adult allergy clinic. * Positive food-specific IgE (≥2.0 kUA/L) to the relevant food OR a positive skin-prick test with a wheal ≥4 mm larger than the saline control. * Positive open oral food challenge at baseline screening evaluation to the relevant food with dose-limiting symptoms at a single dose of ≤1000 mg (cumulative dose of ≤2043 mg) prior to starting omalizumab (using incremental doses of 3, 10, 30, 100, 300, 600, 1000 mg). * Prior authorization from the patient's insurance provider for clinical use of omalizumab. Exclusion Criteria: * Clinically significant laboratory abnormalities in the past 6 months. * Sensitivity or suspected/known allergy to any ingredients (including excipients) of omalizumab * Poorly controlled or severe asthma/wheezing at screening * History of severe anaphylaxis to the participant-specific food that will be used in this study, defined as neurological compromise or requiring intubation. * Currently receiving oral, intramuscular (IM), or intravenous (IV) corticosteroids, tricyclic antidepressants, or β-blockers. * Past or current history of cancer, or currently being investigated for possible cancer. * Past or current history of any food immunotherapy, such as oral immunotherapy (OIT), sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT) within 6 months of screening. * Treatment with monoclonal antibody therapy, such as omalizumab, dupilumab, benralizumab, mepolizumab, reslizumab, tezepelumab, or other immunomodulatory therapy within 6 months of screening. * Inability to discontinue antihistamines for minimum wash-out periods required for skin-prick test or oral food challenge. * Pregnant or breastfeeding, or intending to become pregnant during the study * Evidence of clinically significant chronic disease.

Locations (1)

Johns Hopkins Hospital

Baltimore, Maryland, United States